BioNTech SE (NASDAQ:BNTX) Shares Sold by Captrust Financial Advisors

Captrust Financial Advisors cut its position in BioNTech SE (NASDAQ:BNTX) by 70.8% in the third quarter, HoldingsChannel reports. The institutional investor owned 3,678 shares of the company’s stock after selling 8,909 shares during the period. Captrust Financial Advisors’ holdings in BioNTech were worth $437,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Planning Capital Management Corp boosted its stake in shares of BioNTech by 45,000.0% in the third quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after purchasing an additional 450 shares during the period. Blue Trust Inc. boosted its position in BioNTech by 491.1% in the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after buying an additional 388 shares during the period. GAMMA Investing LLC grew its stake in shares of BioNTech by 21.7% in the third quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock worth $74,000 after acquiring an additional 111 shares in the last quarter. Daiwa Securities Group Inc. increased its position in shares of BioNTech by 430.3% during the second quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company’s stock worth $155,000 after acquiring an additional 1,562 shares during the period. Finally, Caprock Group LLC acquired a new stake in shares of BioNTech in the second quarter valued at $206,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Stock Up 1.1 %

BNTX stock opened at $120.69 on Friday. BioNTech SE has a one year low of $76.53 and a one year high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The company has a fifty day moving average of $113.91 and a 200-day moving average of $100.17. The stock has a market capitalization of $28.93 billion, a PE ratio of -57.47 and a beta of 0.22.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. The company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm’s revenue for the quarter was up 38.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.73 EPS. As a group, analysts expect that BioNTech SE will post -3.72 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Berenberg Bank started coverage on BioNTech in a research report on Tuesday, November 19th. They issued a “buy” rating and a $130.00 price target on the stock. Wells Fargo & Company started coverage on shares of BioNTech in a report on Wednesday. They set an “overweight” rating and a $170.00 price target for the company. BMO Capital Markets restated an “outperform” rating on shares of BioNTech in a report on Monday, December 2nd. JPMorgan Chase & Co. lowered their target price on shares of BioNTech from $124.00 to $122.00 and set a “neutral” rating for the company in a research note on Tuesday, November 26th. Finally, Morgan Stanley raised BioNTech from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $93.00 to $145.00 in a research report on Tuesday, September 24th. Four research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $140.76.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.